

PRA Health Sciences Inc

Just Good Ol' Fashioned Execution

Accelerating book to bill bodes well

With a string of solid results, mgmt reiterated that the company continues to execute against plan. The solid book to bill of 1.25 was driven primarily by execution of generating new business from new and existing customers. Mgmt highlighted that the company signed another strategic client during the quarter which did not add to bookings during the quarter, making the company's 1.25 book to bill all the more impressive. For the strategic client, bookings from the client are expected to begin rolling in sometime in 4Q15, but the bookings are more a 2016 event from mgmt's view. While cancellations were up modestly as a % of beginning backlog, mgmt did not note any major events related to the cancellations. We note the cancellation rate of 3.4% is well within industry norms.

Emerging biotech still a good area for PRAH

With the pharmaceutical and biotech space seeing some pressure over the past couple of months, there have been some questions on how the possible slowdown in biotech funding could impact CROs over time. PRAH mgmt noted that while the company works with emerging biotech companies, the backlog is not heavily weighted towards the emerging biotech space. Further, mgmt noted that the company initially started with emerging biotech but the companies have since been acquired by larger pharmaceutical companies which may remove some of the overhang of working with a non-revenue generating entity.

Still room for margin expansion and other tidbits

On the margin expansion, mgmt continues to feel good about how the company is executing and noted that if FX changes, the company could be paid in local currencies, etc. While there was no guidance on margin trends from here, mgmt feels there is continued opportunity to keep costs down in SG&A and direct costs. Separately, PRAH's largest client ticked up to 11.4% during the quarter but is expected to remain at 11% for the full year. Mgmt also noted that FX only provided a \$0.01 benefit to EPS during the quarter. Altogether, the results and underlying trends point to continued strength for the remainder of 2015 and into 2016.

Valuation: Buy rated with \$47 PT 21x P/E our CY16 EPSe of \$2.22

\$47 PT is based on 21x P/E on our CY16E EPS of \$2.22; equals 13x EBITDA.

Equities

Americas
Healthcare Providers

12-month rating **Buy**

12m price target **US\$47.00**

Price **US\$37.75**

RIC: PRAH.O **BBG:** PRAH US

Trading data and key metrics

52-wk range	US\$45.44-0.00
Market cap.	US\$2.40bn
Shares o/s	63.5m (COM)
Free float	100%
Avg. daily volume ('000)	219
Avg. daily value (m)	US\$8.6
Common s/h equity (12/15E)	US\$0.70bn
P/BV (12/15E)	3.4x
Net debt / EBITDA (12/15E)	3.4x

EPS (UBS, diluted) (US\$)

	12/15E	
	UBS	Cons.
Q1	0.41	0.41
Q2	0.47	0.47
Q3	0.52	0.52
Q4E	0.50	0.48
12/15E	1.90	1.83
12/16E	2.22	2.13
12/17E	2.56	2.44

Steven Valiquette

Analyst
steven.valiquette@ubs.com
+1-212-713 9427

Jonathan Yong

Associate Analyst
jonathan.yong@ubs.com
+1-212-713 6268

Highlights (US\$m)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Revenues	597	833	1,267	1,368	1,484	1,603	1,723	1,844
EBIT (UBS)	81	113	162	227	252	279	309	337
Net earnings (UBS)	32	25	56	120	142	166	191	216
EPS (UBS, diluted) (US\$)	0.80	0.61	1.26	1.90	2.22	2.56	2.92	3.28
DPS (US\$)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net (debt) / cash	(345)	(1,184)	(857)	(831)	(686)	(522)	(343)	(150)
Profitability/valuation	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
EBIT margin %	13.6	13.5	12.8	16.6	17.0	17.4	17.9	18.3
ROIC (EBIT) %	-	-	10.4	15.2	17.4	20.5	24.0	27.6
EV/EBITDA (core) x	-	-	-	12.9	11.3	9.7	8.3	7.2
P/E (UBS, diluted) x	-	-	-	19.8	17.0	14.8	12.9	11.5
Equity FCF (UBS) yield %	-	-	-	4.4	6.4	7.2	7.8	8.4
Net dividend yield %	-	-	-	0.0	0.0	0.0	0.0	0.0

Source: Company accounts, Thomson Reuters, UBS estimates. Metrics marked as (UBS) have had analyst adjustments applied. Valuations: based on an average share price that year, (E): based on a share price of US\$37.75 on 02 Nov 2015 19:39 EST

www.ubs.com/investmentresearch

This report has been prepared by UBS Securities LLC. **ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 10.** UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Investment Thesis

PRA Health Sciences Inc

Investment case

PRA Health Sciences is a CRO focused primarily on the late-stage clinical trial market segment, with a niche therapeutic approach in both CNS and oncology (among others). Of great importance, PRA seems to have greater customer mix in the faster growing biotech and small- to mid-size pharma customer base, which we believe should allow the company to consistently report top-line growth that is at least in line with overall industry growth. PRA derives ~40% of sales from biotech companies (one of the highest in the industry). PRAH's recent acquisitions should bolster the company's future prospects and we rate PRAH a Buy with a price target of \$47 based on a P/E of 21x our 2016 EPS estimate of \$2.22.

Upside scenario

In our upside scenario to our thesis, PRAH will sign a strategic partnership with a major top 10 pharmaceutical company. This contract along with growth in the market and better economics as the company streamlines acquisitions would warrant a higher P/E multiple given the EPS growth from the contract. Applying a hypothetical 23x PE to an EPS estimate of \$2.22 equates to a valuation of \$51/sh.

Downside scenario

In the downside scenario to our thesis, the company could lose a strategic partner while seeing difficulties in the integration of the various acquisitions completed over the past few years. The integration issues could materialize in higher costs which could result in a hypothetical lower 2016E EPS of \$1.93. On a slightly lower multiple of ~17x, this leads to a valuation of \$33/sh.

Upcoming catalysts

November 2015 – various investor conferences

12-month rating

Buy

12m price target

US\$47.00


Business description

PRA Health Sciences Inc. is a contract research organization. The company provides biopharmaceutical development services to pharmaceutical and biotechnology companies. The company has historically catered to smaller biotech and pharma companies. During 2013, PRAH acquired CRL Lifetree, ClinStar, and RPS. The acquisition of RPS greatly expanded the company's relationships with large pharma companies while providing a global presence to conduct clinical trials. The company IPOed in November 2014.

Industry outlook


The CRO industry has been growing at a steady clip, primarily the result of significant growth in the phase II-IV market. However, we expect the early development market to have relatively flat growth through 2018. We expect the overall CRO industry to grow at a CAGR of ~6-7% through 2018, with CRO market penetration accelerating through the years. We expect the CRO market penetration to increase from ~42% in 2013 to ~52% in 2018. We expect the largest CROs to be the primary beneficiaries of increased outsourcing trends.

Revenues by region (2014)



Source: Company documents

Revenues by Customer Segment (2014)



Source: Company documents

Figure 1: PRA Health – 2015 Guidance Table

PRA Health: Company Guidance Table					
Guidance For Period: Date Announced:	FY15 2/18/2015	FY15 5/6/2015	FY15 7/27/2015	FY15 11/2/2015	4Q15 11/2/2015
Consolidated Services Revenues	\$1.35 - 1.40 bil	\$1.34 - 1.39 bil	\$1.34 - 1.39 bil	\$1.365 - 1.370 bil	\$351.4 - 356.4 bil
Effective Tax Rate	30.0%	30.0%	30.0%	30.0%	30.0%
Non-GAAP Diluted EPS	\$1.35 - 1.45	\$1.62 - 1.72	\$1.75 - 1.85	\$1.89 - 1.92	\$0.48 - 0.51
Non-GAAP EPS Y-O-Y Growth	+7 - 15%	+29 - 37%	+39 - 47%	+51 - 54%	+36 - 45%
GAAP Diluted EPS	\$0.60 - 0.65	\$0.70 - 0.80	\$0.80 - 0.90	\$1.00 - 1.05	
FX	Assumes 1/1/15 rates	Assumes 4/1/15 rates	Assumes July '15 rates	Assumes Oct. 15, 2015 Rates	Assumes Oct. 15, 2015 Rates
Note:					

Source: Company reports

Figure 2: PRA Health – Quarterly Revenue Model & Statistics (\$ mil)

PRAH - Quarterly Revenue Model (\$ mil)								
	PRAH 03/31/14 Actual	PRAH 06/30/14 Actual	PRAH 09/30/14 Actual	PRAH 12/31/14 Actual	PRAH 03/31/15 Actual	PRAH 06/30/15 Actual	PRAH 09/30/15 Actual	PRAH 12/31/15 Projected
Revenues:								
Gross Revenues	\$354.7	\$357.5	\$377.3	\$370.0	\$388.6	\$392.8	\$403.5	\$405.1
Reimbursable Revenue	(43.4)	(46.1)	(57.3)	(46.2)	(56.6)	(56.3)	(58.4)	(50.6)
Net Revenues	\$311.4	\$311.4	\$320.1	\$323.8	\$332.0	\$336.5	\$345.1	\$354.5
Yr/Yr Growth	87.0%	73.5%	70.1%	8.4%	6.6%	8.1%	7.8%	9.5%
Backlog:								
Backlog	\$1,987	\$2,045	\$2,091	\$2,141	\$2,200	\$2,262	\$2,348	\$2,425
Yr/Yr Growth	39.8%	41.6%	42.7%	10.4%	10.7%	10.6%	12.3%	13.3%
Gross New business	\$422.8	\$423.8	\$442.0	\$456.8	\$444.3	\$462.4	\$507.4	\$502.5
Net New business	\$351.3	\$371.9	\$382.0	\$388.4	\$398.0	\$407.8	\$431.4	\$427.1
Net new business growth y-o-y	91.7%	86.6%	101.3%	92.4%	13.3%	9.7%	12.9%	10.0%
Net book-to-bill ratio	1.13	1.19	1.19	1.20	1.20	1.21	1.25	1.20
Cancellations As a % of Beginning Backlog	(\$71.5) 3.7%	(\$51.9) 2.6%	(\$60.0) 2.9%	(\$68.4) 3.3%	(\$46.3) 2.2%	(\$54.6) 2.5%	(\$76.0) 3.4%	(\$75.4) 3.2%
Burn Rate	16.1%	15.7%	15.7%	15.5%	15.5%	15.3%	15.3%	15.1%
Net revenue % by geographical area								
US/Canada	57.5%	58.7%	56.0%	59.7%	60.8%	61.1%	60.3%	--
Europe/Africa	34.1%	33.1%	33.0%	31.8%	30.4%	29.5%	30.2%	--
Asia Pacific	3.9%	4.2%	5.0%	4.1%	4.1%	4.1%	5.4%	--
Latin America	4.5%	4.0%	6.0%	4.4%	4.7%	5.3%	4.1%	--
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	--
Net revenue by geographical area								
US/Canada	\$179.1	\$182.9	\$179.2	\$193.4	\$202.0	\$205.7	\$208.1	--
Europe/Africa	106.1	103.0	105.6	102.9	101.0	99.2	104.1	--
Asia Pacific	12.3	13.0	16.0	13.4	13.4	13.8	18.8	--
Latin America	13.9	12.5	19.2	14.1	15.5	17.8	14.1	--
Total	\$311.4	\$311.4	\$320.1	\$323.8	\$332.0	\$336.5	\$345.1	--

Source: Company documents; UBS estimates

Figure 3: PRA Health Sciences – Quarterly Income Statement (\$ mil)

PRAH - Quarterly Income Statement (\$ mil)								
Revenues	PRAH 03/31/14 Actual	PRAH 06/30/14 Actual	PRAH 09/30/14 Actual	PRAH 12/31/14 Actual	PRAH 03/31/15 Actual	PRAH 06/30/15 Actual	PRAH 09/30/15 Actual	12/31/15 Projected
Total Revenue	\$311.4	\$311.4	\$320.1	\$323.8	\$332.0	\$336.5	\$345.1	\$354.5
% change	87.0%	73.5%	70.1%	8.4%	6.6%	8.1%	7.8%	9.5%
Expenses								
COGS	215.2	213.4	215.7	214.9	219.0	219.9	212.8	231.1
% of revenue	69.1%	68.5%	67.4%	66.4%	66.0%	65.3%	61.7%	65.2%
Gross Profit (incl stock comp exp)	96.2	98.0	104.3	108.8	113.0	116.6	132.3	123.4
% of revenue	30.9%	31.5%	32.6%	33.6%	34.0%	34.7%	38.3%	34.8%
SG&A (incl stock comp exp)	60.8	56.0	63.4	61.8	60.8	58.9	63.1	62.0
% of revenue	19.5%	18.0%	19.8%	19.1%	18.3%	17.5%	18.3%	17.5%
Stock Comp (Addback to EBITDA)	(0.9)	(0.9)	(1.0)	(0.7)	(0.8)	(1.2)	(1.6)	(1.0)
Other Op Exp. (Addback to EBITDA)	(3.5)	(2.6)	(5.2)	(2.9)	(2.8)	(2.3)	4.2	(2.0)
<i>Adjusted EBITDA check line</i>	<i>39.7</i>	<i>45.5</i>	<i>47.0</i>	<i>50.6</i>	<i>55.7</i>	<i>61.3</i>	<i>66.6</i>	
Adjusted EBITDA	39.7	45.5	47.0	50.6	55.7	61.3	66.6	64.3
% of revenue	12.8%	14.6%	14.7%	15.6%	16.8%	18.2%	19.3%	18.1%
Depreciation (ex Deal Amortization)	5.9	4.9	4.5	5.4	5.1	5.1	5.4	5.5
% of revenue	1.9%	1.6%	1.4%	1.7%	1.5%	1.5%	1.6%	1.6%
Other expense exclude from net income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
% of revenue	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating Income	33.8	40.6	42.5	45.2	50.6	56.2	61.2	58.8
% of revenue	10.9%	13.0%	13.3%	14.0%	15.2%	16.7%	17.7%	16.6%
Interest Expense (Income), net	20.3	19.4	21.0	17.0	13.7	13.8	13.7	13.6
Other Expense (income), net	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pretax Income	13.5	21.2	21.5	28.2	36.9	42.5	47.4	45.2
% of revenue	4.3%	6.8%	6.7%	8.7%	11.1%	12.6%	13.7%	12.8%
Income Taxes	4.6	7.2	7.3	9.6	11.1	12.7	14.2	13.6
Tax Rate (%)	34.0%	34.0%	34.0%	34.0%	30.0%	30.0%	30.0%	30.0%
Minority Interest (Income)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income	8.907	13.994	14.181	18.644	25.8	29.7	33.2	31.7
% of revenue	2.9%	4.5%	4.4%	5.8%	7.8%	8.8%	9.6%	8.9%
	\$0.22	\$0.34	\$0.34	\$0.35	\$0.41	\$0.47	\$0.52	\$0.50
EPS - Fully Diluted	\$0.22	\$0.34	\$0.34	\$0.35	\$0.41	\$0.47	\$0.52	\$0.50
% change	1.9%	14.2%	-313.9%	37.7%	87.5%	37.3%	55.2%	41.1%
Fully Diluted Shares (mil.)	40.6	40.7	42.1	53.0	62.8	63.0	63.5	63.8
P&L Line Growth Comparison:								
Revenues	87.0%	73.5%	70.1%	8.4%	6.6%	8.1%	7.8%	9.5%
COGS	114.8%	101.2%	86.7%	4.8%	1.8%	3.0%	-1.4%	7.5%
Gross Profit (incl stock comp exp)	45.0%	33.6%	43.7%	16.1%	17.5%	19.0%	26.8%	13.4%
SG&A (incl stock comp exp)	15.4%	25.0%	25.0%	-4.0%	0.0%	5.2%	-0.5%	0.4%
EBITDA	35.6%	37.6%	42.5%	43.6%	40.3%	34.9%	41.6%	27.0%
Depreciation and Amortization	42.3%	23.4%	1.3%	-1.3%	-13.0%	3.6%	20.6%	1.5%
Operating Income	34.5%	39.6%	48.9%	51.8%	49.6%	38.6%	43.9%	30.1%
Interest Expense	108.3%	75.8%	78.0%	-16.5%	-32.4%	-28.8%	-34.8%	-19.9%
Pretax Income	-12.3%	17.5%	28.4%	198.4%	173.2%	100.2%	120.8%	60.1%
Net Income	-1.5%	10.7%	-314.3%	79.8%	189.8%	112.4%	134.2%	69.8%
EPS	1.9%	14.2%	-313.9%	37.7%	87.5%	37.3%	55.2%	41.1%
Shares Outstanding	-3.3%	-3.1%	0.2%	30.6%	54.5%	54.7%	50.9%	20.4%
Dividend Per Share	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

Source: Company documents; UBS estimates

Figure 4: PRA Health Sciences – Annual Revenue Model & Statistics (\$ mil)

PRAH - Annual Revenue Model								
	PRAH FY12 Actual	PRAH FY13 Actual	PRAH FY14 Actual	FY15 Projected	FY16 Projected	FY17 Projected	FY18 Projected	FY19 Projected
Revenues:								
Gross Revenues	\$699.7	\$991.3	\$1,459.6	\$1,590.0	\$1,725.2	\$1,863.2	\$2,003.0	\$2,143.2
Reimbursable Revenue	(102.7)	(158.4)	(193.0)	(221.9)	(241.0)	(260.3)	(279.8)	(299.4)
Net Revenues	\$699.7	\$832.9	\$1,266.6	\$1,368.1	\$1,484.2	\$1,602.9	\$1,723.1	\$1,843.7
Yr/Yr Growth	27.8%	19.0%	52.1%	8.0%	8.5%	8.0%	7.5%	7.0%
Backlog:								
Backlog	\$1,383	\$1,940	\$2,141	\$2,425	\$2,605	\$2,792	\$2,983	\$3,178
Yr/Yr Growth	5.2%	40.3%	10.4%	13.3%	7.4%	7.1%	6.9%	6.5%
Gross New business	\$947.8	\$997.7	\$1,745.4	\$1,916.6	\$2,062.2	\$2,216.9	\$2,372.1	\$2,526.3
Net New business	\$653.5	\$774.3	\$1,493.6	\$1,664.3	\$1,789.1	\$1,914.4	\$2,038.8	\$2,161.1
Net new business growth y-o-y	-11.3%	18.5%	92.9%	11.4%	7.5%	7.0%	6.5%	6.0%
Net book-to-bill ratio	0.93	0.93	1.18	1.22	1.21	1.19	1.18	1.17
Cancellations	\$294.3	\$223.4	\$251.8	\$252.3	\$273.1	\$302.5	\$333.3	\$365.1
As a % of Beginning Backlog	22.4%	16.2%	13.0%	11.8%	11.3%	11.6%	11.9%	12.2%
Burn Rate	11.4%	14.5%	15.7%	15.3%	15.3%	15.4%	15.4%	15.5%
Net revenue % by geographical area								
US/Canada	53.9%	52.7%	58.0%	--	--	--	--	--
Europe/Africa	40.8%	41.0%	33.0%	--	--	--	--	--
Asia Pacific	3.2%	3.2%	4.3%	--	--	--	--	--
Latin America	2.1%	3.2%	4.7%	--	--	--	--	--
Total	100%	100%	100%	--	--	--	--	--
Net revenue by geographical area								
US/Canada	\$321.7	\$438.9	\$734.6	--	--	--	--	--
Europe/Africa	243.8	341.1	417.7	--	--	--	--	--
Asia Pacific	19.3	26.4	54.7	--	--	--	--	--
Latin America	12.3	26.5	59.7	--	--	--	--	--
Total	\$597.1	\$832.9	\$1,266.6	--	--	--	--	--

Source: Company documents; UBS estimates

Figure 5: PRA Health Sciences – Annual Income Statement (\$ mil)

PRAH - Annual Income Statement (Millions)								
Revenues	PRAH FY12 Actual	PRAH FY13 Actual	PRAH FY14 Actual	FY15 Projected	FY16 Projected	FY17 Projected	FY18 Projected	FY19 Projected
Total Revenue	\$597.1	\$832.9	\$1,266.6	\$1,368.1	\$1,484.2	\$1,602.9	\$1,723.1	\$1,843.7
% change	9.0%	39.5%	52.1%	8.0%	8.5%	8.0%	7.5%	7.0%
Expenses								
COGS	358.6	526.9	859.2	882.8	960.3	1,035.5	1,111.4	1,189.2
% of revenue	60.1%	63.3%	67.8%	64.5%	64.7%	64.6%	64.5%	64.5%
Gross Profit (incl stock comp exp)	238.5	306.0	407.4	485.3	523.9	567.4	611.7	654.5
% of revenue	39.9%	36.7%	32.2%	35.5%	35.3%	35.4%	35.5%	35.5%
SG&A (incl stock comp exp)	160.6	212.6	242.1	244.9	258.2	274.1	289.5	304.2
% of revenue	26.9%	25.5%	19.1%	17.9%	17.4%	17.1%	16.8%	16.5%
Stock Comp (Addback to EBITDA)	(11.6)	(24.7)	(3.5)	(4.6)	(5.0)	(5.0)	(6.0)	(7.0)
Other Op Exp. (Addback to EBITDA)	(6.7)	(12.4)	(14.1)	(2.9)	(4.0)	(5.0)	(5.5)	(6.0)
<i>Adjusted EBITDA check line</i>	<i>96.2</i>	<i>130.6</i>	<i>182.8</i>					
Adjusted EBITDA	96.2	130.6	182.8	248.0	274.7	303.3	333.7	363.3
% of revenue	16.1%	15.7%	14.4%	18.1%	18.5%	18.9%	19.4%	19.7%
Depreciation (ex Deal Amortization)	15.0	18.1	20.7	21.1	23.0	24.0	25.0	26.0
% of revenue	2.5%	2.2%	1.6%	1.5%	1.5%	1.5%	1.5%	1.4%
Other expense exclude from net income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
% of revenue	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating Income	81.1	112.5	162.1	226.8	251.7	279.3	308.7	337.3
% of revenue	13.6%	13.5%	12.8%	16.6%	17.0%	17.4%	17.9%	18.3%
Interest Expense (Income), net	28.5	52.9	77.7	54.8	50.0	45.0	40.0	35.0
Other Expense (income), net	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pretax Income	52.6	59.6	84.4	172.0	201.7	234.3	268.7	302.3
% of revenue	8.8%	7.2%	6.7%	12.6%	13.6%	14.6%	15.6%	16.4%
Income Taxes	20.7	34.2	28.7	51.6	59.5	68.2	77.4	86.2
Tax Rate (%)	39.4%	57.3%	34.0%	30.0%	29.5%	29.1%	28.8%	28.5%
Minority Interest (Income)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income	31.9	25.4	55.7	120.4	142.2	166.1	191.3	216.2
% of revenue	5.3%	3.1%	4.4%	8.8%	9.6%	10.4%	11.1%	11.7%
<i>Reported EPS from Cont. Ops.</i>	<i>\$0.80</i>	<i>\$0.61</i>	<i>\$1.26</i>					
EPS - Fully Diluted	\$0.80	\$0.61	\$1.26	\$1.90	\$2.22	\$2.56	\$2.92	\$3.28
% change	-4.6%	-24.0%	108.5%	50.7%	16.7%	15.1%	14.3%	12.1%
Fully Diluted Shares (mil.)	40.0	42.0	44.1	63.3	64.0	65.0	65.5	66.0
P&L Line Growth Comparison:								
Revenues	9.0%	39.5%	52.1%	8.0%	8.5%	8.0%	7.5%	7.0%
COGS	11.6%	46.9%	63.1%	2.7%	8.8%	7.8%	7.3%	7.0%
Gross Profit (incl stock comp exp)	5.3%	28.3%	33.1%	19.1%	8.0%	8.3%	7.8%	7.0%
SG&A (incl stock comp exp)	16.1%	32.3%	13.9%	1.2%	5.5%	6.1%	5.6%	5.1%
EBITDA	1.2%	35.8%	40.0%	35.6%	10.8%	10.4%	10.0%	8.9%
Depreciation and Amortization	13.6%	20.0%	14.8%	2.0%	8.8%	4.3%	4.2%	4.0%
Operating Income	-0.9%	38.7%	44.1%	39.9%	10.9%	11.0%	10.5%	9.3%
Interest Expense	-9.1%	85.6%	46.9%	-29.4%	-8.8%	-10.0%	-11.1%	-12.5%
Pretax Income	4.3%	13.3%	41.6%	103.7%	17.2%	16.2%	14.7%	12.5%
Net Income	-6.0%	-20.2%	119.1%	116.1%	18.1%	16.9%	15.2%	13.0%
EPS	-4.6%	-24.0%	108.5%	50.7%	16.7%	15.1%	14.3%	12.1%
Shares Outstanding	-1.5%	5.0%	5.1%	43.4%	1.2%	1.6%	0.8%	0.8%
Dividend Per Share	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

Source: Company documents; UBS estimates

PRA Health Sciences Inc (PRAH.O)

	12/12	12/13	12/14	12/15E	% ch	12/16E	% ch	12/17E	12/18E	12/19E
Income statement (US\$m)										
Revenues	597	833	1,267	1,368	8.0	1,484	8.5	1,603	1,723	1,844
Gross profit	239	306	407	485	19.1	524	8.0	567	612	655
EBITDA (UBS)	96	131	183	248	35.6	275	10.8	303	334	363
Depreciation & amortisation	(15)	(18)	(21)	(21)	2.0	(23)	8.8	(24)	(25)	(26)
EBIT (UBS)	81	113	162	227	39.9	252	10.9	279	309	337
Associates & investment income	0	0	0	0	-	0	-	0	0	0
Other non-operating income	0	0	0	0	-	0	-	0	0	0
Net interest	(28)	(53)	(78)	(55)	29.4	(50)	8.8	(45)	(40)	(35)
Exceptionals (incl goodwill)	0	0	0	0	-	0	-	0	0	0
Profit before tax	53	60	84	172	103.7	202	17.2	234	269	302
Tax	(21)	(34)	(29)	(52)	-79.7	(59)	-15.3	(68)	(77)	(86)
Profit after tax	32	25	56	120	116.1	142	18.1	166	191	216
Preference dividends	0	0	0	0	-	0	-	0	0	0
Minorities	0	0	0	0	-	0	-	0	0	0
Extraordinary items	0	0	0	0	-	0	-	0	0	0
Net earnings (local GAAP)	32	25	56	120	116.1	142	18.1	166	191	216
Net earnings (UBS)	32	25	56	120	116.1	142	18.1	166	191	216
Tax rate (%)	39.4	57.3	34.0	30.0	-11.8	29.5	-1.7	29.1	28.8	28.5
Per share (US\$)										
EPS (UBS, diluted)	0.80	0.61	1.26	1.90	50.7	2.22	16.7	2.56	2.92	3.28
EPS (local GAAP, diluted)	0.80	0.61	1.26	1.90	50.7	2.22	16.7	2.56	2.92	3.28
EPS (UBS, basic)	0.80	0.61	1.26	1.90	50.7	2.22	16.7	2.56	2.92	3.28
Net DPS (US\$)	0.00	0.00	0.00	0.00	-	0.00	-	0.00	0.00	0.00
Cash EPS (UBS, diluted) ¹	1.17	1.04	1.73	2.24	29.1	2.58	15.3	2.93	3.30	3.67
Book value per share	4.40	11.13	11.32	11.05	-2.3	11.92	7.8	13.07	14.58	16.44
Average shares (diluted)	40.00	42.00	44.12	63.26	43.4	64.00	1.2	65.00	65.50	66.00
Balance sheet (US\$m)										
Cash and equivalents	-	81	92	83	-9.0	169	102.2	273	391	524
Other current assets	215	377	400	483	21.0	531	9.8	588	656	734
Total current assets	-	458	491	567	15.4	699	23.4	861	1,047	1,258
Net tangible fixed assets	650	1,875	1,707	1,636	-4.2	1,550	-5.2	1,463	1,376	1,288
Net intangible fixed assets	0	0	0	0	-	0	-	0	0	0
Investments / other assets	8	62	42	46	10.2	46	0.0	46	46	46
Total assets	-	2,395	2,241	2,249	0.4	2,296	2.1	2,370	2,469	2,593
Trade payables & other ST liabilities	303	450	466	509	9.3	552	8.6	600	654	707
Short term debt	3	19	0	20	-	20	0.00	20	20	20
Total current liabilities	306	469	466	529	13.6	572	8.2	620	674	727
Long term debt	451	1,246	949	894	-5.7	834	-6.7	774	714	654
Other long term liabilities	50	212	150	126	-15.6	126	0.0	126	126	126
Preferred shares	0	0	0	0	-	0	-	0	0	0
Total liabilities (incl pref shares)	807	1,927	1,564	1,550	-0.9	1,533	-1.1	1,521	1,514	1,508
Common s/h equity	176	467	677	699	3.3	763	9.1	849	955	1,085
Minority interests	0	0	0	0	-	0	-	0	0	0
Total liabilities & equity	983	2,395	2,241	2,249	0.4	2,296	2.1	2,370	2,469	2,593
Cash flow (US\$m)										
Net income (before pref divs)	32	25	56	120	116.1	142	18.1	166	191	216
Depreciation & amortisation	15	18	21	21	2.0	23	8.8	24	25	26
Net change in working capital	47	58	(16)	(26)	-60.5	15	-	12	5	(5)
Other operating	16	(31)	17	25	47.3	10	-59.4	10	10	10
Operating cash flow	110	70	77	141	82.0	190	35.3	212	231	247
Tangible capital expenditure	(18)	(20)	(27)	(34)	-25.5	(37)	-7.9	(40)	(45)	(45)
Intangible capital expenditure	0	0	0	0	-	0	-	0	0	0
Net (acquisitions) / disposals	0	(1,115)	0	0	-	0	-	0	0	0
Other investing	0	(5)	15	(58)	-	0	-	0	0	0
Investing cash flow	(18)	(1,140)	(12)	(92)	NM	(37)	59.9	(40)	(45)	(45)
Equity dividends paid	(102)	(132)	0	0	-	0	-	0	0	0
Share issues / (buybacks)	0	470	334	3	-99.1	10	230.4	10	10	10
Other financing	(2)	(59)	(7)	(3)	63.48	0	-	0	0	0
Change in debt & pref shares	61	798	(319)	(35)	89.02	(60)	-71.43	(60)	(60)	(60)
Financing cash flow	(42)	1,078	8	(34)	-	(50)	-44.9	(50)	(50)	(50)
Cash flow inc/(dec) in cash	50	8	73	14	-81.3	103	NM	122	136	152
FX / non cash items	-	(36)	(63)	(22)	65.0	(18)	17.8	(18)	(18)	(19)
Balance sheet inc/(dec) in cash	-	(28)	11	(8)	-	85	-	104	118	133

Source: Company accounts, UBS estimates. (UBS) metrics use reported figures which have been adjusted by UBS analysts.¹Cash EPS (UBS, diluted) is calculated using UBS net income adding back depreciation and amortization.

PRA Health Sciences Inc (PRAH.O)

Valuation (x)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
P/E (local GAAP, diluted)	-	-	-	19.8	17.0	14.8	12.9	11.5
P/E (UBS, diluted)	-	-	-	19.8	17.0	14.8	12.9	11.5
P/CEPS	-	-	-	16.9	14.6	12.9	11.4	10.3
Equity FCF (UBS) yield %	-	-	-	4.4	6.4	7.2	7.8	8.4
Net dividend yield (%)	-	-	-	0.0	0.0	0.0	0.0	0.0
P/BV x	-	-	-	3.4	3.2	2.9	2.6	2.3
EV/revenues (core)	-	-	-	2.3	2.1	1.8	1.6	1.4
EV/EBITDA (core)	-	-	-	12.9	11.3	9.7	8.3	7.2
EV/EBIT (core)	-	-	-	14.1	12.4	10.6	9.0	7.7
EV/OpFCF (core)	-	-	-	16.5	14.4	12.3	10.6	8.9
EV/op. invested capital	-	-	-	2.1	2.2	2.2	2.2	2.1
Enterprise value (US\$m)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Market cap.	-	-	-	2,397	2,397	2,397	2,397	2,397
Net debt (cash)	345	765	1,020	844	759	604	433	247
Buy out of minorities	0	0	0	0	0	0	0	0
Pension provisions/other	0	0	0	0	0	0	0	0
Total enterprise value	-	-	-	3,241	3,156	3,001	2,830	2,644
Non core assets	(8)	(17)	(41)	(46)	(46)	(46)	(46)	(46)
Core enterprise value	-	-	-	3,195	3,110	2,955	2,784	2,598
Growth (%)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Revenue	9.0	39.5	52.1	8.0	8.5	8.0	7.5	7.0
EBITDA (UBS)	1.2	35.8	40.0	35.6	10.8	10.4	10.0	8.9
EBIT (UBS)	-0.9	38.7	44.1	39.9	10.9	11.0	10.5	9.3
EPS (UBS, diluted)	-4.6	-24.0	108.5	50.7	16.7	15.1	14.3	12.1
Net DPS	-	-	-	-	-	-	-	-
Margins & Profitability (%)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Gross profit margin	39.9	36.7	32.2	35.5	35.3	35.4	35.5	35.5
EBITDA margin	16.1	15.7	14.4	18.1	18.5	18.9	19.4	19.7
EBIT margin	13.6	13.5	12.8	16.6	17.0	17.4	17.9	18.3
Net earnings (UBS) margin	5.3	3.1	4.4	8.8	9.6	10.4	11.1	11.7
ROIC (EBIT)	-	-	10.4	15.2	17.4	20.5	24.0	27.6
ROIC post tax	-	2.9	6.8	10.7	12.3	14.5	17.1	19.8
ROE (UBS)	18.1	7.9	9.7	17.5	19.4	20.6	21.2	21.2
Capital structure & Coverage (x)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Net debt / EBITDA	3.6	9.1	4.7	3.4	2.5	1.7	1.0	0.4
Net debt / total equity %	196.2	253.3	126.6	118.8	89.9	61.4	36.0	13.9
Net debt / (net debt + total equity) %	66.2	71.7	55.9	54.3	47.3	38.1	26.5	12.2
Net debt/EV %	-	-	-	26.0	22.1	17.7	12.3	5.8
Capex / depreciation %	120.1	109.2	131.8	162.1	160.9	166.7	180.0	173.1
Capex / revenue %	3.0	2.4	2.2	2.5	2.5	2.5	2.6	2.4
EBIT / net interest	2.8	2.1	2.1	4.1	5.0	6.2	7.7	9.6
Dividend cover (UBS)	-	-	-	-	-	-	-	-
Div. payout ratio (UBS) %	-	-	-	-	-	-	-	-
Revenues by division (US\$m)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Others	597	833	1,267	1,368	1,484	1,603	1,723	1,844
Total	597	833	1,267	1,368	1,484	1,603	1,723	1,844
EBIT (UBS) by division (US\$m)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Others	81	113	162	227	252	279	309	337
Total	81	113	162	227	252	279	309	337

Source: Company accounts, UBS estimates. (UBS) metrics use reported figures which have been adjusted by UBS analysts.

Forecast returns

Forecast price appreciation	+24.5%
Forecast dividend yield	0.0%
Forecast stock return	+24.5%
Market return assumption	5.8%
Forecast excess return	+18.7%

Statement of Risk

The primary risk factors for PRA Health include: 1) Risk of expansion / contraction of pharmaceutical and biotech drug company research and development budgets, particularly late-stage; 2) Risk of increase/decrease in the trend of pharmaceutical and biotechnology company outsourcing of drug research and development specifically with respect to late-stage development; 3) Risk of changes to government regulations required in the process of drug research and development; 4) Risk of a loss of any strategic partner relationships or the cancellation of a project. The company also bares financial risk in regards to contracts that may be mis-priced or otherwise overrun initial cost estimates.

Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is > 6% above the MRA.	49%	33%
Neutral	FSR is between -6% and 6% of the MRA.	40%	26%
Sell	FSR is > 6% below the MRA.	12%	18%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%

Source: UBS. Rating allocations are as of 30 September 2015.

1:Percentage of companies under coverage globally within the 12-month rating category. 2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category. 4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: **UK and European Investment Fund ratings and definitions are:** **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Steven Valiquette; Jonathan Yong.

Company Disclosures

Company Name	Reuters	12-month rating	Short-term rating	Price	Price date
PRA Health Sciences Inc ^{2, 4, 5, 6, 16}	PRAH.O	Buy	N/A	US\$37.75	02 Nov 2015


Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.
5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
6. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided.
16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

PRA Health Sciences Inc (US\$)



Source: UBS; as of 02 Nov 2015

Global Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo, the UBS Client Portal and UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g. market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

For access to all available Global Research on UBS Neo and the Client Portal, please contact your UBS sales representative.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ('the Information'), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this

document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Italia Sim S.p.A. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 018/09/2015 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). Clients of UBS Wealth Management Australia Ltd: Distributed by UBS Wealth Management Australia Ltd (Holder of Australian Financial Services License No. 231127). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg. **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Prepared by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2015. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

